Adenomyosis is the invasion of the endometrium and mesenchyme into the myometrium and diffuse growth in it, called adenomyosis. Due to different diagnostic techniques and criteria, the reported incidence varies widely by country, race and hospital, fluctuating between 10% and 70%. Adenomyosis has become a common gynecological disease that can develop from adolescence to postmenopause, but is more common in women of childbearing age, with clinical symptoms such as progressive aggravation of dysmenorrhea, excessive menstruation, irregular menstruation, anemia, and infertility. It seriously affects the life and work of women. At present, the most important treatment for adenomyosis is still sex hormone therapy, whose myology is to stop or inhibit the periodic bleeding of ectopic endometrial tissue. Therefore, drug hormone therapy cannot cure adenomyosis, but can only control the development of symptoms and lesions, and relapse inevitably occurs after stopping drug therapy. At the same time, the side effects of sex hormone drugs also have certain effects on patients, such as liver function damage, osteoporosis, vaginal dryness and weight gain, acne, hirsutism and other side effects, which seriously affect patients’ psychological and quality of life. Therefore, hysterectomy is currently the only effective radical means. Uterine artery embolization technique for adenomyosis is a vascular interventional technique developed in the last decade or so, with remarkable recent efficacy and 80%-90% control of symptoms of dysmenorrhea and excessive menstrual flow. Its embolization keys and techniques include: the selection of embolization material; the mastery of the degree of embolization; the preparation of embolization material; the speed of embolization; the protection of the ovarian branch of the uterine artery and the treatment of the ovarian artery during embolization. However, this technique also has risks to the ovary, the risk of decreased ovarian function or ovarian failure after embolization, and the key to its prevention is the protection of the ovarian branch of the uterine artery during embolization. However, its two-year recurrence rate is too high. Therefore, its use has been controversial. For interventional radiologists, the high recurrence rate is unacceptable; however, for obstetrics and gynecology, where more than half of patients can resolve their symptoms and preserve their uterus, interventional embolization is the hope for adenomyosis! However, with an in-depth review of the literature, we found that the literature with a high recurrence rate two years after interventional treatment of adenomyosis has the disadvantage of a low number of cases, a high rate of missed visits, and inconsistent criteria for evaluating efficacy; therefore, a high recurrence rate of two years should be analyzed with caution and should not be judged as a high recurrence rate of this technique for adenomyosis. With the publication of studies with a larger number of cases, reports of long-term follow-up (4-5 years) and our experience, the long-term recurrence rate of this technique is not as high as in the earlier literature, and the long-term recurrence rate is lower than in the earlier studies, with 82% of patients having good symptom control in the long term (more than 5 years). Thus, there is once again hope for interventional embolization of adenomyosis! The key to the success rate of this technique lies in: 1) clarifying which patients are effective for interventional therapy; 2) decision making in interventional therapy; and 3) the most critical aspect of interventional therapy is the technique of embolization. Correct mastery of the above key points is what will make embolization interventions a hope for adenomyosis!